Background: Atrial fibrillation (AF) is associated with increased morbidity in acute coronary syndrome patients, but impact on outcomes beyond 1 year is unclear. Methods: This was a post-hoc analysis from the long-tErm follow-uP of antithrombotic management patterns In acute CORonary syndrome patients (EPICOR) registry (NCT01171404), a prospective, observational study conducted in Europe and Latin America, which enrolled acute coronary syndrome survivors at discharge. Antithrombotic management patterns, mortality, a composite endpoint of death/new non-fatal myocardial infarction/stroke and bleeding events were assessed after 2 years of follow-up in patients with or without AF. Results: Of 10,568 patients enrolled, 397 (4.7%) had prior AF and 382 (3.6%) new-onset AF during index hospitalisation. Fewer patients with AF underwent percutaneous coronary intervention (52.1% vs. 66.6%; P<0.0001). At discharge, fewer AF patients received dual antiplatelet therapy (71.6% vs. 89.5%; P<0.0001); oral anticoagulant use was higher in AF patients but was still infrequent (35.0% vs. 2.5%; P<0.0001). Use of dual antiplatelet therapy and oral anticoagulants declined over follow-up with over 50% of all AF/no AF patients remaining on dual antiplatelet therapy (55.6% vs. 60.6%), and 23.3% (new-onset AF) to 42.1% (prior AF) on oral anticoagulants at 2 years. At 2 years, mortality, composite endpoint and bleeding rates were higher in AF patients (all P<0.0001) compared to patients without AF. On multivariable analysis, the risk of mortality or the composite endpoint was significant for prior AF (P=0.003, P=0.001) but not newonset AF (P=0.88, P=0.92). Conclusions: Acute coronary syndrome patients with AF represent a high-risk group with increased event rates during long-term follow-up. Prior AF is an independent predictor of mortality and/or ischaemic events at 2 years. Use of anticoagulants in AF after acute coronary syndrome is still suboptimal.
Introduction
Known or new-onset atrial fibrillation (AF) is a relatively common comorbid condition or complication in patients with acute coronary syndromes (ACSs), and is observed in 4-12% of ACS patients. 1, 2 The existence of prior AF is associated with increased morbidity and mortality on top of the risk incurred by ACS, both in hospital and up to 1 year post-discharge, [2] [3] [4] but any impact on outcomes beyond 1 year has not yet been prospectively elucidated. 1 It should perhaps be noted that this study was performed before many of the newer and more effective antithrombotic agents became available, e.g. ticagrelor. In 2006, European Society of Cardiology (ESC) guidelines recommended antithrombotic therapy to prevent thromboembolism for most patients with AF; in particular, anticoagulation with a vitamin K antagonist was recommended for patients with more than one moderate risk factor, combined with low-dose aspirin and/or clopidogrel following percutaneous coronary intervention (PCI). 5 In contrast, recent guidelines recommend revascularisation therapies and the use of intensive antithrombotic therapies in AF patients, including triple therapy with a combination of dual antiplatelet therapy (DAPT) and an oral anticoagulant (OAC), particularly those with a CHA 2 DS 2 -VASc (cardiac failure, hypertension, age ≥75 [doubled], diabetes, stroke [doubled] -VAScular disease, age 65-74 and sex category [female]) score of 2 or greater, with the key aim of stroke prevention. [6] [7] [8] [9] However, the risk of bleeding is increased considerably with triple therapy compared with DAPT. 10, 11 As both ischaemic and bleeding complications are associated with impaired prognosis, the difficulty lies in achieving a balance between reducing the risk of cardiovascular events and increasing the risk of bleeding, with consideration given to multiple factors, including individual patient characteristics, choice and duration of therapy and, when relevant, choice of stent.
The long-tErm follow-uP of antithrombotic management patterns In acute CORonary syndrome patients (EPICOR) registry (NCT01171404) was primarily designed to describe the frequency of different antithrombotic management patterns in a real-life setting in patients surviving hospitalisation for ACS, with a 2-year follow-up period. 12 The aim of this post-hoc analysis was to determine antithrombotic management patterns and long-term (2-year) post-discharge mortality and cardiovascular event rates in ACS patients with or without AF, including known prior AF or new-onset, inhospital AF, in a real-life setting.
Methods

Study design
EPICOR was a multinational, observational, prospective cohort study conducted in 555 hospitals in 20 countries across four regions of the world: Eastern, northern and southern Europe, and Latin America. Full details of the EPICOR rationale and study design, definitions, inhospital and long-term results have been published previously. [12] [13] [14] Briefly, patients aged at least 18 years who survived hospitalisation for confirmed ST-segment elevation myocardial infarction (STEMI), or non-ST-segment elevation acute coronary syndrome (NSTE-ACS; including non-STEMI and unstable angina) were enrolled at discharge from hospital and followed up for 2 years. Exclusion criteria included 'secondary' ACS (precipitated by or occurring as a complication of surgery, trauma, PCI, or other reasons), any serious comorbidities considered likely to limit life expectancy to less than 6 months, and prior enrolment in EPICOR.
Events were adjudicated by the local investigators. Data were collected using electronic case report forms, including details of acute phase (from symptom onset to discharge) and long-term management and outcomes, the latter by telephone follow-up every 3 months by trained interviewers. All patients were required to have been hospitalised within 24 hours of symptom onset, and to provide written informed consent. The final protocol was approved by the ethics committees of participating centres in accordance with each country's local regulations.
Objectives
The primary objective of the EPICOR registry was to evaluate acute and long-term antithrombotic management patterns in ACS patients in a real-life setting. A full list of secondary endpoints has been reported previously, and included evaluation of inhospital and post-discharge clinical outcomes (ischaemic and bleeding events). 12 The objectives of this post-hoc analysis were to compare patient characteristics, inhospital and discharge antithrombotic management patterns, and clinical outcomes (mortality, cardiovascular events and bleeding events) at 2 years according to the presence or absence of AF, including known prior AF and new-onset AF (see Supplementary  Figure 1 ). Known prior AF included all AF diagnosed before admission for the index event, even if it was no longer present, and AF that was ongoing at admission. New-onset AF included only AF that started during the index hospitalisation; patients with prior AF (no longer ongoing) that re-emerged during the index hospitalisation were included in the prior AF group rather than the newonset AF group.
Statistical analysis
Comparisons of patient characteristics, inhospital and discharge antithrombotic management and ischaemic and bleeding events between patients with and without AF were performed with Pearson's chi-squared test.
Multivariable logistic regression analysis was performed to assess the effect of baseline patient characteristics on inhospital intervention, antithrombotic medication and cardiac complications. Univariable and multivariable Cox proportional hazards models were used to assess the effect of prior, new-onset or any AF on either 2-year mortality or a composite endpoint of death, non-fatal myocardial infarction (MI), or non-fatal stroke within 2 years. For each model, the assumption of proportional hazards was tested using Schoenfeld residuals. The baseline variables adjusted for in the multivariable models are those previously found to be predictive of mortality when the EPICOR dataset was used to create a risk score: 15 age (per 10 years), left ventricular ejection fraction (LVEF) less than 40% and less than 30%, EuroQol 5 dimensions (EQ-5D) score (per unit), serum creatinine (per unit ≥1.2 mg/dL), other cardiac complications in hospital (MI/recurrent ischaemia, cardiogenic shock, heart failure, or any other arrhythmia), blood glucose of 160 mg/dL or greater, chronic obstructive pulmonary disease, male gender, diagnosis (STEMI vs. NSTE-ACS), PCI or coronary artery bypass graft (CABG), haemoglobin less than 13 g/dL, peripheral vascular disease, on diuretics at discharge, and region (Eastern Europe, Latin America, northern Europe, southern Europe).
Results
Patients
A total of 10,568 ACS patients were enrolled in EPICOR between 1 September 2010 and 31 March 2011, of whom 497 (4.7%) had known prior AF at baseline and 382 (3.6%) had new-onset AF during the index event (see Supplementary Figure 1 , Table 1 ). Data were missing for 134 patients (117 for prior AF and 21 for new-onset AF, including four patients with missing data for both categories of AF). Patients with any AF were more likely than those without to have a diagnosis of NSTE-ACS (64.3% vs. 35.7%), were older (mean 70.5% vs. 60.9 years; age ≥65 years 70.9% vs. 37.3%), were less often men (66.9% vs. 75.8%), had higher proportions of LVEF less than 30% (5.5% vs. 2.2%), serum creatinine of 1.2 mg/dL or greater (34.8% vs. 20.3%), and blood glucose of 160 mg/dL or greater (28.8% vs. 22.6%) and a higher mean CHA 2 DS 2 -VASc score (3.0 vs. 1.7) (all P<0.001) ( Table 1) . Patients with AF were also more likely to have comorbidities, such as peripheral vascular disease (10.2% vs. 4.6%) and chronic obstructive pulmonary disease (11.4% vs. 6.1%) (both P<0.001) ( Table 1) , and a poorer quality of life, as indicated by higher EQ-5D scores (P<0.001).
Management
Despite an apparently higher cardiovascular risk level than patients without AF, those with AF underwent coronary angiography significantly less frequently (P<0.05) ( Table 1) , or were treated with PCI (P<0.001) (see Supple mentary Figure 2 ). In contrast, patients with new-onset AF were more likely to undergo CABG (P<0.001) (see Supplementary Figure 2 ). The overall revascularisation rate (PCI and CABG combined) for patients with versus without AF Table 1) . In most cases, the differences derived mainly from the population with prior AF. Conversely, patients with AF were more likely to receive low molecular weight heparin (LMWH) (51.1% vs. 46.9%; P=0.017) due to greater use in patients with new-onset AF (60.2%), and more were treated with OACs (warfarin/acenocoumarol in most cases: 27.3% vs. 2.0%; P<0.001). The use of fibrinolysis was low, particularly in AF patients (5.6% vs. 8.6%; P<0.001). After adjustment for baseline characteristics, significance disappeared for many of the AF versus no-AF differences, but remained for prasugrel (P=0.002), DAPT (P=0.006), LMWH (P=0.028) and OACs (P<0.001) (see Supplementary Table 1 ). It should be noted that the results for some parameters (e.g. use of aspirin for management of the index event) were significant but in opposite directions for prior and new-onset AF, effectively cancelling out the effect for any AF.
A similar pattern was observed for discharge medication, with fewer AF than non-AF patients receiving DAPT (71.6% vs. 89.5%; P<0.0001) (see Supplementary   Figure 3 (a)), and more AF patients discharged on OACs, albeit only one-third of them (35.0% vs. 2.5%; P<0.0001), most of whom were on warfarin/acenocoumarol. Among AF patients, OAC use at discharge was low despite many (~90% of prior AF patients) having a CHA 2 DS 2 -VASc score of 2 or greater, but was higher in those with prior AF than new-onset AF (42.9% vs. 24.9%). These included a relatively small percentage of AF patients who were discharged on an OAC plus a single antiplatelet (13.5% vs. 0.8% for any vs. no AF), most of which was in patients with prior AF (17.3%). Therapy consisting of DAPT plus an OAC was more frequently given at discharge in AF versus no-AF patients, including prior AF (19.9% vs. 2.0%), newonset AF (14.1% vs. 2.4%) and any AF (17.0% vs. 1.5%). By the end of follow-up, the differences in management pattern persisted, with over half of all AF and no-AF patients remaining on DAPT at 2 years (55.6% vs. 60.6%), and 17.2% of any AF patients on TAPT (Figure 1 and Supplementary Figure 3(b) ). The use of any OAC in AF patients declined over time; to 42.1% of prior AF patients, and 23.3% of those with new-onset AF, at 2 years.
Cardiovascular and bleeding complications inhospital
Patients with any AF were significantly more likely to have other inhospital cardiovascular or bleeding complications than those without AF (31.2% vs. 16.1%; P<0.001), including MI/recurrent ischaemia (7.7% vs. 5.5%), cardiogenic shock (2.3% vs. 0.9%), heart failure (16.0% vs. 4.8%), any other arrhythmia (8.9% vs. 4.7%), stroke (0.7% vs. 0.2%) and bleeding (5.8% vs. 3.0%) ( 
001).
However, the higher inhospital complication rates in AF patients derived from those with new-onset rather than prior AF. After adjustment for baseline variables, the differences remained significant but marginally less so for prior versus no prior AF (P=0.034) (see Supplementary Table 2 ).
Two year clinical outcomes
At 2 years of follow-up post-discharge, the proportion of patients who had died was significantly higher among ACS patients with prior AF versus no prior AF (15.1% vs. 5.2%), new-onset AF (9.9% vs. 5.6%), or any AF (12.9% vs. 5.0%) (all P<0.0001) (Figure 2 and Supplementary Figure 4 ). Significant differences in the same direction were also observed for the composite endpoint of death, non-fatal MI or non-fatal stroke, and for bleeding events (all P<0.0001 except new-onset vs. no new-onset AF bleeding events; P=0.0001). The number of patients with the individual components of non-fatal MI and non-fatal stroke was small, and no statistical comparisons were performed, but non-fatal MI was numerically less frequent in patients with than without new-onset AF (1.0% vs. 1.9%), whereas non-fatal stroke was more frequent in all categories of patients with AF.
Univariable and multivariable analysis
Univariable and multivariable analysis provided significance for many variables, including for mortality and the composite endpoint.
Mortality. On univariable analysis, the hazard ratio (HR, 95% confidence interval (CI)) for risk of death was significantly higher in patients with prior AF, new-onset AF or any AF (3. 
Discussion
The results of this analysis of 2-year follow-up data from the EPICOR registry demonstrate that AF, particularly prior AF, is a major contributor to inhospital cardiac complications and an increased risk of mortality and cardiovascular events in the long term. Furthermore, despite guideline recommendations, 6, 8, 10 fewer AF patients underwent PCI (52% compared with 67% of non-AF patients), only 72% were discharged on DAPT (compared with 90% of non-AF patients), and only 35% were discharged on OAC therapy (43% with prior AF and 25% with new-onset AF) even though the majority had a CHA 2 DS 2 -VASc score of 2 or greater. At the end of follow-up, the use of any OAC in AF patients had declined to 34%. While triple therapy was used in 17% of AF patients at discharge, combination therapy with an OAC and a single antiplatelet was used in 14%. Consistent findings were reported in a recent European Heart Rhythm Association (EHRA) survey, an internet questionnaire-based study, in which only 15 (41%) of 37 centres routinely administered triple therapy to all AF patients following PCI, and 22 (59%) centres used them in AF patients with moderate to high thromboembolic risk. 11 Over 90% of centres surveyed used a combination of aspirin, clopidogrel and warfarin.
Despite the relatively low use of OACs at discharge in EPICOR, there was a significantly greater long-term risk of bleeding events in AF patients, both prior and new-onset. Stroke was reported infrequently during follow-up, but was numerically more likely to occur in patients with any category of AF. The majority were discharged on warfarin/ acenocoumarol, whereas evidence indicates that the newer, non-vitamin K oral anticoagulants (NOACs) have a more favourable risk profile. 16 However, given recent reports of lower bleeding rates with NOACs compared with vitamin K antagonists, when used in combination with antiplatelet agents after an ACS and/or PCI, it can be speculated that current OAC use will be higher. 17, 18 In addition, multivariable analysis of the data from EPICOR showed that adjustment for other variables resulted in important changes in terms of the cardiovascular risk associated with AF. Multivariable analysis reconfirmed the increased risk of events in ACS patients with AF; that is, after adjustment for other baseline predictor variables, prior AF remained associated with worse outcomes of both death (HR 1.48, 95% CI 1.14-1.90; P=0.003), and the composite endpoint of death, non-fatal MI or non-fatal stroke (HR 1.46, 95% CI 1.16-1.83; P=0.001). These results suggest that prior AF, but not new-onset AF, is an independent predictor of an increased risk of both mortality and the composite endpoint of death, non-fatal MI or non-fatal stroke. The lower risk of clinical events associated with new-onset AF might be related not only to the lower risk profile but in addition to the fact that some patients may have had AF only in the acute phase related to the ischaemia, and maintained thereafter in sinus rhythm.
Limitations of this study include it being a substudy, potential bias or inaccuracy in reporting of the follow-up data due to the 3-month interval between telephone calls, changes in the availability of antithrombotic drugs over the study duration, and investigator-led adjudication of clinical events. Also, as the population included only hospital survivors, there is no means of determining whether AF is associated with early, inhospital, mortality. Finally, the analysis did not account for cardiac rhythm at hospital discharge. It may well be that, in patients with new-onset AF, outcomes differ in those with AF persisting at discharge versus those in sinus rhythm at discharge.
In conclusion, in clinical practice, patients with ACS and AF (known prior and new-onset) are treated less frequently with revascularisation therapies, and more than half do not receive oral anticoagulation at discharge, with a decline in use over time. They also experience a high event rate during long-term follow-up, with increased mortality, and cardiovascular and bleeding events compared with ACS patients without AF. Multivariable analysis indicates that prior AF is an independent predictor of both mortality and the composite endpoint of death, non-fatal MI or nonfatal stroke during the first 2 years after discharge, whereas new-onset AF is not. Every effort should be made to increase the rate of guideline-adherent therapies in these high-risk patients after ACS. The adoption of a more personalised management approach, addressing individual patient risk factors, as well as closer follow-up may also help to improve long-term outcomes in patients with AF.
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